FDA grant approval for new paediatric indication for Lymphoseek (technetium Tc 99m tilmanocept) injection

The new indication for this radioactive diagnostic agent is based on a study showing the radiopharmaceutical is safe & effective for patients aged ≥1 month with no serious adverse reactions to the drug being reported and <1% reporting injection site irritation.

Source:

Biospace Inc.